Apremilast
Tier B — Position earlyApremilast · all drugs expiring in 2028 →
Targets：PDE4
Brand：Otezla
Indications (approved)：Plaque psoriasis, Behçet's syndrome, Oral ulcer, Psoriasis, Psoriatic arthritis
Regional status
Factories producing this API1
Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.
1 producing factories on file — sign in to view the named list (factory details are not shown to guests).
Sign in to view factories →Synthetic routes & intermediates6 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| APER-001 | 1131-52-8 | 3-ethoxy-4-methoxybenzaldehyde |
| APER-002 | 253168-94-4 | 1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethan-1-amine |
| APER-003 | 1188-21-2 | (2S)-2-acetamido-4-methylpentanoic acid |
| APER-004 | 608141-43-1 | (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethanamine (S)-2-acetamido-4-methylpentanoate |
| APER-005 | 6296-53-3 | N-(1,3-dioxo-1,3-dihydroisobenzofuran-4-yl)acetamide |
| APER-006 | 603-11-2 | 3-nitrophthalic acid |
| APER-007 | 5434-20-8 | 3-aminophthalic acid |
| Code | CAS No. | Intermediate |
|---|---|---|
| APER-001 | 1131-52-8 | 3-ethoxy-4-methoxybenzaldehyde |
| APER-002 | 253168-94-4 | 1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethan-1-amine |
| APER-006 | 603-11-2 | 3-nitrophthalic acid |
| APER-008 | 60758-86-3 | 3-ethoxy-4-methoxybenzonitrile |
| APER-009 | 641-70-3 | 4-nitroisobenzofuran-1,3-dione |
| APER-010 | 253168-82-0 | 2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4-nitroisoindoline-1,3-dione |
| APER-011 | 253168-83-1 | 4-amino-2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)isoindoline-1,3-dione |
| Code | CAS No. | Intermediate |
|---|---|---|
| APER-001 | 1131-52-8 | 3-ethoxy-4-methoxybenzaldehyde |
| APER-005 | 6296-53-3 | N-(1,3-dioxo-1,3-dihydroisobenzofuran-4-yl)acetamide |
| APER-012 | 219897-35-5 | (R)-1-(amino(phenyl)methyl)naphthalen-2-ol |
| APER-013 | 1616367-18-0 | (1R,3S)-3-(3-ethoxy-4-methoxyphenyl)-1-phenyl-2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazine |
| APER-014 | 199600-54-9 | lithium (methylsulfonyl)methanide |
| APER-015 | 1616367-19-1 | 1-((R)-(((S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)amino)(phenyl)methyl)naphthalen-2-ol |
| APER-016 | 608141-42-0 | (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethanamine |
| Code | CAS No. | Intermediate |
|---|---|---|
| APER-005 | 6296-53-3 | N-(1,3-dioxo-1,3-dihydroisobenzofuran-4-yl)acetamide |
| APER-008 | 60758-86-3 | 3-ethoxy-4-methoxybenzonitrile |
| APER-016 | 608141-42-0 | (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethanamine |
| APER-017 | 1450657-31-4 | (E)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethenamine |
| Code | CAS No. | Intermediate |
|---|---|---|
| APER-001 | 1131-52-8 | 3-ethoxy-4-methoxybenzaldehyde |
| APER-008 | 60758-86-3 | 3-ethoxy-4-methoxybenzonitrile |
| APER-016 | 608141-42-0 | (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethanamine |
| APER-017 | 1450657-31-4 | (E)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethenamine |
| APER-018 | 1450657-28-9 | 1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethanone |
| APER-019 | 2627-86-3 | (S)-1-phenylethan-1-amine |
| APER-020 | 1450759-47-3 | 1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)-N-((S)-1-phenylethyl)ethanamine hydrochloride |
| APER-021 | 196929-78-9 | (R)-2-methylpropane-2-sulfinamide |
| APER-022 | 1450759-43-9 | (E)-N-(3-ethoxy-4-methoxybenzylidene)-2-methylpropane-2-sulfinamide |
| APER-023 | 1450759-44-0 | N-((S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-2-methylpropane-2-sulfinamide |
| Code | CAS No. | Intermediate |
|---|---|---|
| APER-003 | 1188-21-2 | (2S)-2-acetamido-4-methylpentanoic acid |
| APER-018 | 1450657-28-9 | 1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethanone |
| APER-024 | 1450657-24-5 | (R)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethanol |
| APER-025 | 1450657-43-8 | (S)-4-(1-azido-2-(methylsulfonyl)ethyl)-2-ethoxy-1-methoxybenzene |
| APER-026 | 608141-43-1 | (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethanamine (S)-2-acetamido-4-methylpentanoate |
Frequently asked questions
What are the approved indications of Apremilast?
Approved indications include: Plaque psoriasis, Behçet's syndrome, Oral ulcer, Psoriasis, Psoriatic arthritis.
When does the Apremilast patent expire?
Based on public sources, the Apremilast patent expires in 2028.
How many synthesis routes are recorded for Apremilast?
6 synthesis routes are recorded; the shortest is 3 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Apremilast intermediates?
All intermediates in Apremilast routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Apremilast intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29